NASDAQ:VIRI

Virios Therapeutics Competitors

$5.58
+0.06 (+1.09 %)
(As of 04/16/2021 04:00 PM ET)
Add
Compare
Today's Range
$5.37
Now: $5.58
$5.87
50-Day Range
$5.01
MA: $5.86
$6.80
52-Week Range
$4.60
Now: $5.58
$16.71
Volume54,419 shs
Average Volume200,098 shs
Market Capitalization$46.48 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A

Competitors

Virios Therapeutics (NASDAQ:VIRI) Vs. GANX, ANVS, VINC, EVAX, LGVN, and UPC

Should you be buying VIRI stock or one of its competitors? Companies in the industry of "biotechnology" are considered alternatives and competitors to Virios Therapeutics, including Gain Therapeutics (GANX), Annovis Bio (ANVS), Vincerx Pharma (VINC), Evaxion Biotech A/S (EVAX), Longeveron (LGVN), and Universe Pharmaceuticals (UPC).

Gain Therapeutics (NASDAQ:GANX) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.

Earnings and Valuation

This table compares Gain Therapeutics and Virios Therapeutics' top-line revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain TherapeuticsN/AN/AN/AN/AN/A
Virios TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Gain Therapeutics and Virios Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Gain TherapeuticsN/AN/AN/A
Virios TherapeuticsN/AN/AN/A

Analyst Recommendations

This is a summary of recent ratings for Gain Therapeutics and Virios Therapeutics, as provided by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Gain Therapeutics00203.00
Virios Therapeutics0000N/A

Gain Therapeutics presently has a consensus target price of $30.00, suggesting a potential upside of 106.90%. Given Gain Therapeutics' higher probable upside, analysts plainly believe Gain Therapeutics is more favorable than Virios Therapeutics.

Summary

Gain Therapeutics beats Virios Therapeutics on 2 of the 2 factors compared between the two stocks.

Virios Therapeutics (NASDAQ:VIRI) and Annovis Bio (NYSE:ANVS) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Virios Therapeutics and Annovis Bio, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virios Therapeutics0000N/A
Annovis Bio0000N/A

Earnings & Valuation

This table compares Virios Therapeutics and Annovis Bio's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/AN/AN/AN/A
Annovis BioN/AN/AN/AN/AN/A

Profitability

This table compares Virios Therapeutics and Annovis Bio's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virios TherapeuticsN/AN/AN/A
Annovis BioN/AN/AN/A

Virios Therapeutics (NASDAQ:VIRI) and Vincerx Pharma (NASDAQ:VINC) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, valuation, earnings, profitability, analyst recommendations, dividends and risk.

Earnings & Valuation

This table compares Virios Therapeutics and Vincerx Pharma's top-line revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/AN/AN/AN/A
Vincerx PharmaN/AN/AN/AN/AN/A

Profitability

This table compares Virios Therapeutics and Vincerx Pharma's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virios TherapeuticsN/AN/AN/A
Vincerx PharmaN/AN/AN/A

Analyst Ratings

This is a breakdown of recent recommendations and price targets for Virios Therapeutics and Vincerx Pharma, as provided by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virios Therapeutics0000N/A
Vincerx Pharma00103.00

Given Vincerx Pharma's higher probable upside, analysts clearly believe Vincerx Pharma is more favorable than Virios Therapeutics.

Summary

Vincerx Pharma beats Virios Therapeutics on 2 of the 2 factors compared between the two stocks.

Virios Therapeutics (NASDAQ:VIRI) and Evaxion Biotech A/S (NASDAQ:EVAX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their dividends, analyst recommendations, valuation, institutional ownership, earnings, profitability and risk.

Earnings and Valuation

This table compares Virios Therapeutics and Evaxion Biotech A/S's gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/AN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/AN/AN/A

Profitability

This table compares Virios Therapeutics and Evaxion Biotech A/S's net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virios TherapeuticsN/AN/AN/A
Evaxion Biotech A/SN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Virios Therapeutics and Evaxion Biotech A/S, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virios Therapeutics0000N/A
Evaxion Biotech A/S00203.00

Evaxion Biotech A/S has a consensus price target of $18.00, suggesting a potential upside of 176.07%. Given Evaxion Biotech A/S's higher possible upside, analysts clearly believe Evaxion Biotech A/S is more favorable than Virios Therapeutics.

Summary

Evaxion Biotech A/S beats Virios Therapeutics on 2 of the 2 factors compared between the two stocks.

Longeveron (NASDAQ:LGVN) and Virios Therapeutics (NASDAQ:VIRI) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, dividends, risk, profitability, institutional ownership and earnings.

Analyst Recommendations

This is a summary of current ratings and recommmendations for Longeveron and Virios Therapeutics, as reported by MarketBeat.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Longeveron0000N/A
Virios Therapeutics0000N/A

Earnings & Valuation

This table compares Longeveron and Virios Therapeutics' gross revenue, earnings per share and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
LongeveronN/AN/AN/AN/AN/A
Virios TherapeuticsN/AN/AN/AN/AN/A

Profitability

This table compares Longeveron and Virios Therapeutics' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
LongeveronN/AN/AN/A
Virios TherapeuticsN/AN/AN/A

Virios Therapeutics (NASDAQ:VIRI) and Universe Pharmaceuticals (NYSE:UPC) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, institutional ownership, analyst recommendations, risk, profitability and earnings.

Profitability

This table compares Virios Therapeutics and Universe Pharmaceuticals' net margins, return on equity and return on assets.

Net MarginsReturn on EquityReturn on Assets
Virios TherapeuticsN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/A

Analyst Ratings

This is a breakdown of current ratings and price targets for Virios Therapeutics and Universe Pharmaceuticals, as reported by MarketBeat.com.

Sell RatingsHold RatingsBuy RatingsStrong Buy RatingsRating Score
Virios Therapeutics0000N/A
Universe Pharmaceuticals0000N/A

Earnings & Valuation

This table compares Virios Therapeutics and Universe Pharmaceuticals' revenue, earnings per share (EPS) and valuation.

Gross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Virios TherapeuticsN/AN/AN/AN/AN/A
Universe PharmaceuticalsN/AN/AN/AN/AN/A


Virios Therapeutics Competitors List

Competitor NameCompetitor BTM RankCompetitor PriceCompetitor Price ChangeCompetitor Market CapCompetitor RevenueCompetitor P/E RatioCompetitor Indicator(s)
GANX
Gain Therapeutics
1.7$14.50+2.8%$164.30 millionN/A0.00Analyst Revision
News Coverage
Gap Down
Annovis Bio logo
ANVS
Annovis Bio
0.0$21.55+0.1%$149.71 millionN/A0.00
VINC
Vincerx Pharma
1.0$17.60+4.0%$144.41 millionN/A0.00
EVAX
Evaxion Biotech A/S
1.7$6.52+18.4%$125.18 millionN/A0.00Gap Up
LGVN
Longeveron
0.3$6.52+9.5%$123.60 millionN/A0.00News Coverage
Gap Down
UPC
Universe Pharmaceuticals
0.0$3.87+6.5%$84.17 millionN/A0.00Gap Up
VRDN
Viridian Therapeutics
1.7$14.76+2.8%$57.68 millionN/A0.00Decrease in Short Interest
Gap Up
Inhibikase Therapeutics logo
IKT
Inhibikase Therapeutics
0.0$5.24+3.4%$52.67 millionN/A0.00Gap Down
VIRX
Viracta Therapeutics
1.7$8.00+0.4%$41.39 millionN/A0.00
VYNT
Vyant Bio
0.0$3.65+0.3%$40.18 millionN/A0.00News Coverage
NLS Pharmaceutics logo
NLSP
NLS Pharmaceutics
1.7$3.20+6.3%$37.69 millionN/A0.00News Coverage
VLON
Vallon Pharmaceuticals
0.3$4.55+2.0%$30.99 millionN/A0.00News Coverage
VRPX
Virpax Pharmaceuticals
0.3$4.36+3.2%$23.39 millionN/A0.00Gap Up
CMMB
Chemomab Therapeutics
0.0$27.26+23.2%$12.65 millionN/A0.00Gap Down
BCTX
BriaCell Therapeutics
0.0$3.26+0.6%$2.52 millionN/A0.00News Coverage
ADiTx Therapeutics logo
ADTX
ADiTx Therapeutics
1.0$2.57+4.7%$0.00N/A0.00Gap Up
Apotheca Biosciences logo
CBDC
Apotheca Biosciences
0.4$0.08+0.0%$0.00N/A0.00High Trading Volume
Gap Up
Avid Bioservices logo
CDMOP
Avid Bioservices
0.3$25.06+0.0%$0.00N/A0.00News Coverage
BMEA
Biomea Fusion
0.0N/AN/A$0.00N/A0.00High Trading Volume
RXRX
Recursion Pharmaceuticals
0.0N/AN/A$0.00N/A0.00High Trading Volume
RPHM
Reneo Pharmaceuticals
0.3$13.00+2.4%$0.00N/A0.00Insider Buying
News Coverage
SCPS
Scopus BioPharma
1.4$7.54+3.3%$0.00N/A0.00Increase in Short Interest
News Coverage
Gap Down
VECT
VectivBio
0.0$16.12+1.8%$0.00N/A0.00News Coverage
This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.